Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

Background Three novel direct oral anticoagulants (DOACs) have recently been registered
by the Food and Drug Administration and European Medicines Agency Commission …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …

Direct oral anticoagulants (DOACs) have significantly improved the care of patients requiring
anticoagulation. With similar or better efficacy and safety outcomes and easier use in the …

A new generation of antithrombotic agents, which are conventionally known as direct oral
anticoagulants (DOACs), have recently emerged and are continuing to be developed. These …

A new generation of antithrombotic agents has recently emerged. These provide direct
inhibition of either thrombin (factor IIa [FIIa]) or FXa, and are increasingly replacing the …

Direct oral anticoagulants (DOAC s), including the direct thrombin inhibitor, dabigatran, and
the direct factor Xa (FX a) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for …